Discovery Partners International Newswire

Discovery Partners International Newswire

Comprehensive Real-Time News Feed for Discovery Partners International.

Results 1 - 20 of 122 in Discovery Partners International

  1. Agf Investments Cut Its Nvidia Corp. (NVDA) Holding; Infinity...Read the original story w/Photo

    Yesterday | Hill Country Times

    Agf Investments Inc decreased Nvidia Corp. stake by 19.48% reported in 2017Q4 SEC filing. Agf Investments Inc sold 171,027 shares as Nvidia Corp. 's stock rose 15.49%.

    Comment?

  2. -$0.20 EPS Expected for Infinity Pharmaceuticals, Inc. (INFI) This QuarterRead the original story w/Photo

    Wednesday May 16 | IntersportsWire

    Equities analysts forecast that Infinity Pharmaceuticals, Inc. will post earnings of per share for the current fiscal quarter, according to Zacks Investment Research . Zero analysts have issued estimates for Infinity Pharmaceuticals' earnings, with estimates ranging from to .

    Comment?

  3. William Blair Weighs in on Infinity Pharmaceuticals, Inc.'s Q2 2018 EarningsRead the original story w/Photo

    Friday May 11 | AmericanBankingNews.com

    Infinity Pharmaceuticals, Inc. - Investment analysts at William Blair lowered their Q2 2018 EPS estimates for shares of Infinity Pharmaceuticals in a research note issued on Tuesday, May 8th. William Blair analyst Y. Xu now forecasts that the biotechnology company will earn per share for the quarter, down from their prior forecast of .

    Comment?

  4. Infinity Pharmaceuticals (INFI) Trading Down 5.5%Read the original story w/Photo

    Tuesday May 8 | The Breeze

    Shares of Infinity Pharmaceuticals Inc. fell 5.5% during trading on Tuesday . The company traded as low as $2.03 and last traded at $2.08.

    Comment?

  5. Alan Higginson Unloaded 1,740 Shares of F5 Networks, Inc. (FFIV);...Read the original story w/Photo

    Tuesday May 8 | Hill Country Times

    Infinity Pharmaceuticals Inc had a decrease of 7.82% in short interest. INFI's SI was 2.81 million shares in May as released by FINRA.

    Comment?

  6. Brainstorm Cell Therapeutics Inc. (BCLI) Analysts See $-0.14 EPS;...Read the original story w/Photo

    Saturday May 5 | Hill Country Times

    Analysts expect Brainstorm Cell Therapeutics Inc. to report $-0.14 EPS on May, 21.They anticipate $0.04 EPS change or 40.00% from last quarter's $-0.1 EPS. After having $0.02 EPS previously, Brainstorm Cell Therapeutics Inc.'s analysts see -800.00% EPS growth.

    Comment?

  7. Allergic Asthma Therapeutics Market Outlook to 2025 Aslan...Read the original story

    Friday May 4 | Emailwire.com

    '2018-2025 Allergic Asthma Therapeutics Report on Global and United States Market, Status and Forecast, by Players, Types and Applications' report title add in QY Research Groups database. This report provided upcoming trends in the global market with dri The Global Allergic Asthma Therapeutics Market investigate report gave by QY Research Groups is the most point by point learn about Allergic Asthma Therapeutics that is evaluated to develop at an enormous rate over the figure time frame 2017-2025.

    Comment?

  8. Somewhat Favorable Press Coverage Somewhat Unlikely to Impact...Read the original story w/Photo

    Sunday Apr 29 | IntersportsWire

    Complete the form below to receive the latest headlines and analysts' recommendations for Infinity Pharmaceuticals with our free daily email newsletter:

    Comment?

  9. Millennium Management LLC Grows Stake in Infinity Pharmaceuticals Inc.Read the original story w/Photo

    Friday Apr 27 | AmericanBankingNews.com

    Millennium Management LLC increased its position in shares of Infinity Pharmaceuticals Inc. by 105.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,198,854 shares of the biotechnology company's stock after purchasing an additional 614,806 shares during the period.

    Comment?

  10. Brokerages Expect Infinity Pharmaceuticals Inc. (INFI) to Announce -$0.18 Earnings Per ShareRead the original story w/Photo

    Apr 23, 2018 | AmericanBankingNews.com

    Equities research analysts expect that Infinity Pharmaceuticals Inc. will announce earnings per share of for the current fiscal quarter, according to Zacks Investment Research . Zero analysts have issued estimates for Infinity Pharmaceuticals' earnings, with estimates ranging from to .

    Comment?

  11. Infinity Pharmaceuticals (INFI) Earns Daily Coverage Optimism Score of 0.18Read the original story w/Photo

    Apr 19, 2018 | IntersportsWire

    News stories about Infinity Pharmaceuticals have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time.

    Comment?

  12. Send Press Releases with GlobeNewswireRead the original story

    Apr 19, 2018 | GlobeNewswire

    Orion sues Sun Pharmaceuticals in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo

    Comment?

  13. -$0.18 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This QuarterRead the original story w/Photo

    Apr 14, 2018 | Daily Political

    Brokerages expect Infinity Pharmaceuticals Inc. to report earnings per share for the current quarter, according to Zacks Investment Research . Zero analysts have provided estimates for Infinity Pharmaceuticals' earnings, with the highest EPS estimate coming in at and the lowest estimate coming in at .

    Comment?

  14. Infinity Pharmaceuticals (INFI) Shares Up 9.8% on Insider Buying ActivityRead the original story w/Photo

    Apr 13, 2018 | IntersportsWire

    Shares of Infinity Pharmaceuticals Inc. shot up 9.8% on Thursday after an insider bought additional shares in the company. The company traded as high as $2.34 and last traded at $2.24.

    Comment?

  15. Infinity Pharmaceuticals Inc. (Infi) Stake Maintained by Biotechnology Value Fund L PRead the original story w/Photo

    Apr 12, 2018 | Daily Political

    Biotechnology Value Fund L P recently disclosed that they own a 21.7% stake in Infinity Pharmaceuticals Inc. in a Schedule 13D disclosure that was filed with the Securities and Exchange Commission on Thursday, April 12th. The investor owns 11,276,508 shares of the stock worth approximately $25,259,378.

    Comment?

  16. Brokerages Expect Infinity Pharmaceuticals Inc. (INFI) Will Post Earnings of -$0.18 Per ShareRead the original story w/Photo

    Apr 12, 2018 | IntersportsWire

    Wall Street analysts expect that Infinity Pharmaceuticals Inc. will announce earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Infinity Pharmaceuticals' earnings.

    Comment?

  17. Insider Buying: Infinity Pharmaceuticals Inc. (INFI) Major...Read the original story w/Photo

    Apr 11, 2018 | AmericanBankingNews.com

    Infinity Pharmaceuticals Inc. major shareholder Value Fund L. P. Biotechnology acquired 1,510,000 shares of the stock in a transaction on Tuesday, April 10th. The stock was bought at an average cost of $1.97 per share, for a total transaction of $2,974,700.00.

    Comment?

  18. Bvf Boosted Infinity Pharmaceuticals (INFI) Holding by $3.80 Million; ...Read the original story w/Photo

    Apr 7, 2018 | Hill Country Times

    Bvf Boosted Infinity Pharmaceuticals Holding by $3.80 Million; Amazon Com Position Has Boosted by Coldstream Capital Management Inc Coldstream Capital Management Inc increased its stake in Amazon Com Inc by 20.36% based on its latest 2017Q4 regulatory filing with the SEC. Coldstream Capital Management Inc bought 1,093 shares as the company's stock rose 28.13% while stock markets declined.

    Comment?

  19. -$0.18 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This QuarterRead the original story w/Photo

    Apr 6, 2018 | AmericanBankingNews.com

    Wall Street analysts predict that Infinity Pharmaceuticals Inc. will report earnings of per share for the current quarter, according to Zacks . Zero analysts have made estimates for Infinity Pharmaceuticals' earnings.

    Comment?

  20. Zacks Investment Research Upgrades Infinity Pharmaceuticals (INFI) to "Hold"Read the original story w/Photo

    Apr 6, 2018 | AmericanBankingNews.com

    According to Zacks, "Infinity's clinical trial collaboration with Bristol-Myers for the evaluation of the IPI-549/Opdivo combination bodes well for the company. Meanwhile, Infinity has undertaken a significant organizational restructuring, which includes amending its license agreement with Takeda Oncology for IPI-549.

    Comment?